STOCK TITAN
  1. Home
  2. Sec-filings
  3. IONS
  4. [Form 4] Ionis Pharmaceuticals, Inc. Insider Trading Activity

[Form 4] Ionis Pharmaceuticals, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock IONS logo
Ionis Pharmaceuticals

NASDAQ:IONS

IONS Rankings

#1791 Ranked by Market Cap
N/A Ranked by Dividends

IONS Latest News

Jul 16, 2025
Ionis to hold second quarter 2025 financial results webcast
Jun 25, 2025
Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results
Jun 12, 2025
Ionis announces Dr. Richard Geary, chief development officer, to retire; Dr. Holly Kordasiewicz to assume role in January 2026
Jun 11, 2025
First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome
May 19, 2025
Ionis announces positive topline results from Essence study of olezarsen in people with moderately elevated triglycerides

IONS Latest SEC Filings

Jul 17, 2025
[Form 4] Ionis Pharmaceuticals, Inc. Insider Trading Activity
Jul 17, 2025
[Form 4] Ionis Pharmaceuticals, Inc. Insider Trading Activity
Jul 17, 2025
[Form 4] Ionis Pharmaceuticals, Inc. Insider Trading Activity
Jul 17, 2025
[Form 4] Ionis Pharmaceuticals, Inc. Insider Trading Activity
Jul 17, 2025
[Form 4] Ionis Pharmaceuticals, Inc. Insider Trading Activity

IONS Stock Data

6.82B
155.32M
0.83%
105.1%
8.09%
Biotechnology
Pharmaceutical Preparations
Link
United States
CARLSBAD